Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 08:35:27 2024-04-25 pm EDT			5-day change	1st Jan Change
0.065 ^AUD	+1.56%		+6.56%	-18.75%

Apr. 16	Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing	MT
Mar. 27	Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II	MT

Amplia secures funding to assess AMP945 topical applications

May 22, 2023 at 02:01 pm EDT

(via NewsDirect)

Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns tells Proactive the company has received grant funding to undertake a research collaboration with Australia’s national science agency to develop topical formulations of its FAK inhibitors. Amplia will work with researchers at CSIRO to help develop formulations that could be applied topically to wounds and burns to aid healing and reduce scarring.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Amplia Therapeutics Limited

Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing	Apr. 16	MT
Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II	Mar. 27	MT
Amplia Therapeutics Updates on Pancreatic Cancer Trial; Phase-Two Recruitment Ongoing; Shares Up 3%	Mar. 26	MT
Amplia Therapeutics Secures US FDA Clearance for Proposed Pancreatic Cancer Trial	Jan. 17	MT
Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US	Jan. 17	CI
Amplia Therapeutics Doses First Patient in Phase 2A Pancreatic Cancer Trial	Jan. 16	MT
Amplia Therapeutics Secures South Korean Regulatory Approval for Pancreatic Cancer Trial; Shares Up 3%	Dec. 04	MT
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 20	CI
Amplia Therapeutics Receives AU$2.4 Million R&D Tax Rebate	23-10-18	MT
Amplia Therapeutics Appoints CFO	23-09-25	MT
Amplia Therapeutics Limited Announces Chief Financial Officer Changes	23-09-24	CI
Amplia Therapeutics Gets Nod to Name Drug AMP945 Narmafotinib	23-06-23	MT
Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt	23-05-29	CI
Amplia Therapeutics to Enter Research Collaboration with CSIRO; Shares Rise 7%	23-05-21	MT
Amplia Receives Grant to Collaborate with CSIRO	23-05-21	CI
Amplia Therapeutics Advances Clinical Trial for Pancreatic Cancer Inhibitor Drug	23-05-09	MT
Amplia Therapeutics Doses First Patient for Third Cohort of Pancreatic Cancer Trial; Shares Rise 6%	23-04-18	MT
Amplia Therapeutics Secures Clearance for Third Dose Cohort of Pancreatic Cancer Trial	23-04-11	MT
Amplia Therapeutics Limited Announces Completion of Enrolment of the Second Cohort of Patients in the Ongoing Phase 1b/2a ACCENT Clinical Trial in Frontline Patients with Pancreatic Cancer	23-02-27	CI
Amplia Therapeutics Limited Announces First Patient Recruited to Cohort 2 of Accent Trial in Pancreatic Cancer	23-01-31	CI
Amplia Therapeutics Secures Approval for Dose Escalation Stage of Pancreatic Cancer Trial	23-01-11	MT
Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945	23-01-10	CI
Amplia Therapeutics Enrols First Set of Patients in Clinical Trial of Pancreatic Cancer Treatment	22-11-29	MT
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-17	CI

Chart Amplia Therapeutics Limited

Duration

Period

More charts

Company Profile

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Companyâs pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Companyâs second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AMPLIA THERAPEUTICS LIMITED	-18.75%	8.22M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs